-
Prunin Targets the Senecavirus A IRES
2026-09-01
The reference study identifies prunin as an inhibitor of Senecavirus A replication in cell-based and animal models, with evidence pointing to the viral internal ribosome entry site as a mechanistic target. Its layered design connects antiviral activity with IRES-dependent translation and protein-interaction changes, while also highlighting the need for direct-binding, pharmacokinetic, and safety studies.
-
Adiponectin, TLR4 and Cognitive Deficits in Aged Rats
2026-09-01
This reference study shows that adiponectin pretreatment alleviated splenectomy-associated cognitive deficits in aged rats while reducing hippocampal neuroinflammation and oxidative stress. Pharmacological inhibition and activation experiments implicate the TLR4/MyD88/NF-κB pathway, although the findings remain preclinical and require validation beyond the splenectomy model.
-
HSP90 Regulates RNA Foci in Myotonic Dystrophy Type 1
2026-08-31
Johnson et al. used an unbiased RNA-FISH small-molecule screen to identify HSP90 as a regulator of pathogenic DMPK mRNA and CUG-repeat RNA foci in Myotonic Dystrophy type 1. The study further connects HSP90 activity to p-STAT3 in undifferentiated myoblasts while revealing a differentiation-dependent reversal of the response, providing a framework for studying RNA-foci homeostasis rather than only foci reduction.
-
Gut-Brain Cholinergic Signaling in B. fragilis
2026-08-31
Jia et al. identify a vagal gut-brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, linking colonic ChAT-positive cells with antiseizure activity in mice. The combination of microbiome analysis, neural recordings, circuit manipulation, and a pediatric clinical trial provides a mechanistic framework for microbiota-targeted epilepsy research.
-
GCRV104 Entry Through Clathrin-Mediated Endocytosis
2026-08-30
Wang et al. combined pharmacological inhibition, transmission electron microscopy, and RT-qPCR to show that genotype III grass carp reovirus GCRV104 enters CIK cells through a dynamin-dependent, clathrin-mediated pathway requiring endosomal acidification. The study distinguishes inhibitors that suppress infection from those without measurable activity, providing a useful framework for investigating aquaculture virus entry while highlighting the limits of drug-based pathway assignments.
-
Solanesol (B8776): Practical Workflow Guide
2026-08-29
Solanesol is a hydrophobic polyisoprenoid alcohol for controlled biochemical, membrane-related, and enzyme-focused research workflows. This guide explains DMSO-based preparation, solvent-matched controls, storage, and assay limitations; it should not be used in water- or ethanol-based formulations or for diagnostic, clinical, or medical applications.
-
Tetrazolium (chloride) for Viability Assays
2026-08-28
Tetrazolium (chloride), also called Tetrazolium Red or TTC, converts mitochondrial dehydrogenase activity into a visible red formazan signal. Its flexibility supports both high-throughput cell viability assays and spatial tissue ischemic necrosis detection in stroke and cardiac injury research.
-
Formononetin Protects Against Oxaliplatin Neurotoxicity
2026-08-28
The reference study identifies formononetin as a selective neuroprotective candidate for oxaliplatin-induced peripheral neurotoxicity, acting through Nrf2/HO-1 antioxidant signaling and reduced neuronal apoptosis. Its key translational finding is that neuronal protection was achieved without weakening oxaliplatin or paclitaxel activity in cancer-cell models, although protection against paclitaxel-related neurite damage was limited.
-
Sorafenib: From Kinase Potency to Tumor Phenotype
2026-08-27
Sorafenib and BAY-43-9006 are more than multikinase inhibitors: they enable experiments that separate tumor-cell signaling from endothelial angiogenesis. This guide connects potency data, assay architecture, hepatocellular carcinoma models, and recent VEGFR-2 inhibitor findings to improve mechanistic interpretation.
-
Sodium Phosphate Dibasic for Reliable Bioassays
2026-08-27
Sodium phosphate dibasic (Na2HPO4) is more than a routine buffer ingredient: its chemistry can determine whether biological assay endpoints reflect the test compound or the matrix. This guide connects phosphate-buffer design with aquatic toxicology findings to improve pH control, vehicle matching, and reproducibility.
-
SU 5402 Workflows for RTK Signaling Research
2026-08-26
SU 5402 enables time-resolved interrogation of VEGFR2, FGFR1, PDGFRβ, and downstream ERK1/2–STAT3 signaling across cancer and exploratory human-neuron assays. This practical guide links dose planning, phosphoprotein measurements, cell fate readouts, and troubleshooting to help distinguish pathway inhibition from nonspecific toxicity.
-
7ACC2: Monocarboxylate Transporter 1 Inhibitor
2026-08-26
7ACC2 combines potent MCT1 blockade with interference in mitochondrial pyruvate transport, enabling more informative studies of lactate flux than a single-pathway perturbation. This workflow-focused guide shows how to measure transport, connect tumor metabolism with macrophage immunobiology, and troubleshoot interpretation without overstating translational maturity.
-
ABT-263 (Navitoclax) in Apoptosis Research
2026-08-25
Use ABT-263 (Navitoclax) as a mechanistic benchmark for Bcl-2-family inhibition, dose-response studies, and caspase-dependent apoptosis research. Its value extends into senescence assays, where matched senescent and proliferating controls can reveal whether cell death is selective rather than merely cytotoxic.
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-08-25
Grafton and colleagues developed a scalable assay that combines human induced pluripotent stem cell-derived cardiomyocytes, high-content imaging, and deep learning to identify morphological patterns associated with drug-induced cardiotoxicity. The approach converted complex cellular phenotypes into a single screening score, offering an early de-risking strategy while still requiring electrophysiological and mechanistic validation.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-08-24
The reference study combines genetic models, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its findings support NVP-BGJ398 as a research tool for testing FGFR3 pathway inhibition, while also highlighting the limits of translating mouse growth-plate results directly to human treatment.